Compare GSK plc (GSK) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Williams Companies Inc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Williams Companies Inc trades at $72.67 (market cap $88.48B). The key difference: GSK plc and Williams Companies Inc are close in size by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Williams Companies Inc for 58 Days on average.
| GSK | WMB | |
|---|---|---|
Market Cap | $91.88B | $88.48B |
Volume | 7,730,529 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $61.18 | $79.40 |
52-Week Low | $43.24 | $56.51 |
Typical Hold Time | 93 Days | 58 Days |
Enterprise Value | $111.88B | $119.11B |
Dividend Yield | 3.9% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Williams Companies (WMB) trades at $72.67, up 1.69% today, with strong analyst support (79% buy ratings) and a consensus price target of $87.27. The stock shows bullish technical signals with support at $72 and resistance at $73. Fundamentally, WMB delivered $11.95B revenue in 2025 with 25.18% net income margin, though recent quarterly earnings were mixed with one beat and two misses. The company benefits from stable fee-based revenues in the midstream energy sector.
WMB presents a compelling opportunity with dividend growth potential and exposure to rising natural gas demand from data centers. However, investors face risks from energy market volatility and high debt levels. The stock trades at a premium valuation (P/E 28.82) but offers 3% dividend yield with consistent payout increases. Near-term catalysts include Q3 earnings and AI-driven power demand growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
